Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates-Reference-Cited by-同舟云学术

Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates

Published:2022-11-06 Issue:1 Volume:12 Page:62-73
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacom & Syst Pharma

Author:

Ramakrishnan Vidya¹^ORCID,Friedrich Christina²,Witt Colleen²,Sheehan Robert²,Pryor Meghan²,Atwal Jasvinder K.¹,Wildsmith Kristin¹,Kudrycki Katherine²,Lee Seung‐Hye¹,Mazer Norman³,Hofmann Carsten³,Fuji Reina N.¹,Jin Jin Y.¹^ORCID,Ramanujan Saroja¹,Dolton Michael⁴,Quartino Angelica¹

Affiliation:

1. Genentech, Inc. South San Francisco California USA

2. Rosa & Co., LLC. San Carlos California USA

3. F. Hoffmann‐La Roche Ltd Basel Switzerland

4. Roche Products Australia Pty Ltd New South Wales Sydney Australia

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12876

Reference50 articles.

1. 2021 Alzheimer's disease facts and figures

2. Mild Cognitive Impairment;Petersen RC;Continuum (Minneap Minn),2016

3. Clinical trials of new drugs for Alzheimer disease

4. Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015

5. FDA.FDA Grants Accelerated Approval for Alzheimer's Drug.https://www.fda.gov/news‐events/press‐announcements/fda‐grants‐accelerated‐approval‐alzheimers‐drug. Accessed January 18 2022.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of Model-informed Drug Development (MIDD) in Regulatory Submissions for Drug Approval in Japan;2024-07-18

2. In Vivo Assays for Amyloid-Related Diseases;Annual Review of Analytical Chemistry;2024-07-17

3. Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model;Drugs;2024-06-20

4. Fourteenth American Conference on Pharmacometrics (ACoP14) – Innovation and Diversity: Redefining Pharmacometrics;Journal of Pharmacokinetics and Pharmacodynamics;2024-02-28

5. Passive Immunotherapies Targeting Amyloid-βin Alzheimer’s Disease: A Quantitative Systems Pharmacology Perspective;Molecular Pharmacology;2023-10-31